BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,936 | -14.3% | 307,555 | +2.8% | 0.01% | -13.3% |
| Q2 2023 | $24,422 | +139.9% | 299,165 | +118.0% | 0.02% | +200.0% |
| Q1 2023 | $10,180 | -37.8% | 137,243 | -30.5% | 0.01% | -28.6% |
| Q4 2022 | $16,368 | -99.9% | 197,528 | +397.4% | 0.01% | -41.7% |
| Q3 2022 | $11,278,000 | +13.9% | 39,713 | +39.0% | 0.01% | +100.0% |
| Q2 2022 | $9,901,000 | -53.4% | 28,566 | -41.7% | 0.01% | -64.7% |
| Q1 2022 | $21,225,000 | -69.3% | 49,015 | -63.3% | 0.02% | +30.8% |
| Q4 2021 | $69,134,000 | +128.1% | 133,630 | +113.6% | 0.01% | -7.1% |
| Q3 2021 | $30,314,000 | +36.0% | 62,561 | +26.3% | 0.01% | +27.3% |
| Q2 2021 | $22,294,000 | +1181.3% | 49,515 | +986.8% | 0.01% | +1000.0% |
| Q1 2021 | $1,740,000 | +136.4% | 4,556 | +96.6% | 0.00% | – |
| Q4 2020 | $736,000 | +140.5% | 2,317 | +87.5% | 0.00% | – |
| Q3 2020 | $306,000 | -69.5% | 1,236 | -67.5% | 0.00% | -100.0% |
| Q2 2020 | $1,003,000 | -77.2% | 3,798 | -83.6% | 0.00% | -66.7% |
| Q1 2020 | $4,392,000 | +70.1% | 23,163 | +97.0% | 0.00% | +200.0% |
| Q4 2019 | $2,582,000 | +432.4% | 11,758 | +375.3% | 0.00% | – |
| Q3 2019 | $485,000 | -82.8% | 2,474 | -81.7% | 0.00% | -100.0% |
| Q2 2019 | $2,813,000 | +90.6% | 13,495 | +81.7% | 0.00% | +100.0% |
| Q1 2019 | $1,476,000 | -47.7% | 7,428 | -61.9% | 0.00% | -50.0% |
| Q4 2018 | $2,823,000 | -5.4% | 19,508 | +33.5% | 0.00% | 0.0% |
| Q3 2018 | $2,984,000 | -55.8% | 14,617 | -68.0% | 0.00% | -66.7% |
| Q2 2018 | $6,749,000 | +101.0% | 45,616 | +105.2% | 0.01% | +100.0% |
| Q1 2018 | $3,358,000 | -11.8% | 22,235 | -24.3% | 0.00% | 0.0% |
| Q4 2017 | $3,807,000 | +7.6% | 29,390 | +0.4% | 0.00% | -25.0% |
| Q3 2017 | $3,538,000 | -6.3% | 29,265 | -8.9% | 0.00% | 0.0% |
| Q2 2017 | $3,775,000 | -2.0% | 32,112 | -15.3% | 0.00% | 0.0% |
| Q1 2017 | $3,852,000 | -15.1% | 37,898 | -14.1% | 0.00% | -20.0% |
| Q4 2016 | $4,537,000 | -16.2% | 44,128 | -10.7% | 0.01% | -16.7% |
| Q3 2016 | $5,413,000 | -26.6% | 49,440 | -24.4% | 0.01% | -40.0% |
| Q2 2016 | $7,370,000 | +23.6% | 65,364 | +3.0% | 0.01% | +11.1% |
| Q1 2016 | $5,964,000 | +7.1% | 63,450 | +2.5% | 0.01% | +28.6% |
| Q4 2015 | $5,571,000 | -15.9% | 61,902 | -14.0% | 0.01% | -12.5% |
| Q3 2015 | $6,623,000 | -15.7% | 71,983 | -10.2% | 0.01% | -11.1% |
| Q2 2015 | $7,858,000 | -7.9% | 80,179 | -6.0% | 0.01% | -10.0% |
| Q1 2015 | $8,528,000 | +8.0% | 85,269 | -0.6% | 0.01% | +25.0% |
| Q4 2014 | $7,895,000 | – | 85,807 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |